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Infections caused by community-acquired (CA)-methi-
cillin-resistant Staphylococcus aureus (MRSA) have been
reported worldwide. We assessed whether any common
genetic markers existed among 117 CA-MRSA isolates
from the United States, France, Switzerland, Australia, New
Zealand, and Western Samoa by performing polymerase
chain reaction for 24 virulence factors and the methicillin-
resistance determinant. The genetic background of the
strain was analyzed by pulsed-field gel electrophoresis
(PFGE) and multi-locus sequence typing (MLST). The CA-
MRSA strains shared a type IV SCCmec cassette and the
Panton-Valentine leukocidin locus, whereas the distribution
of the other toxin genes was quite specific to the strains
from each continent. PFGE and MLST analysis indicated
distinct genetic backgrounds associated with each geo-
graphic origin, although predominantly restricted to the
agr3 background. Within each continent, the genetic back-
ground of CA-MRSA strains did not correspond to that of
the hospital-acquired MRSA.
M
ethicillin-resistant  Staphylococcus aureus (MRSA)
are identified as nosocomial pathogens throughout
the world (1). Established risk factors for MRSA infection
include recent hospitalization or surgery, residence in a
long-term–care facility, dialysis, and indwelling percuta-
neous medical devices and catheters. Recently, however,
cases of MRSAhave been documented in healthy commu-
nity-dwelling persons without established risk factors for
MRSA acquisition. Because they are apparently acquired
in the community, these infections are referred to as com-
munity-acquired (CA)-MRSA (2). CA-MRSA infections
have been reported in North America, Europe, Australia,
and New Zealand (3–5). The recent genomic sequence of
a CA-MRSA isolate (6) indicated the presence not only of
a novel smaller variant of the methicillin-resistance locus
(SCCmec IVa, according to Baba et al. designation [6]),
but also that of the locus for the Panton-Valentine leuko-
cidin (PVL). The PVL locus is carried on a bacteriophage
and is present in only a small percentage of S. aureus iso-
lates from France, where this locus is associated with skin
infections, and occasionally, severe necrotizing pneumonia
(7,8).
In a recent study, we found that CA-MRSA infections
in France are caused by a single clone producing the PVL
(3). Analysis of a set of CA-MRSAstrains from the United
States and Australia confirmed the presence of SCCmec
IVa in most of them, and genetic comparison of the CA-
MRSA by multi-locus sequence typing (MLST) indicated
that they belonged to five clonal complexes, two of which
predominated (4). This finding suggested that CA-MRSA
have arisen from diverse genetic backgrounds rather than
the worldwide spread of a single clone (4).
The aim of this study was to determine whether the
PVL gene represents a stable marker of the CA-MRSA
strains worldwide and whether any other common genetic
traits such as toxin gene and the accessory gene regulator
(agr) profiles can be identified.
Materials and Methods
Bacterial Strains
A total of 117 different isolates of CA-MRSA were
examined. Community acquisition was defined as growth
of the isolates within 48 hours after hospital admission in
patients who had no risk factors for nosocomial acquisi-
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Switzerland; and **UMR754, Lyon, France tion, including no hospitalizations or nursing home resi-
dence in the year before admission. Thirty-three isolates
were from the United States. The U.S. isolates all
belonged to the previously identified major CA-MRSA
clonal group and included strain MW2 (2). They originat-
ed from 12 different facilities in Minnesota; two isolates
were from North Dakota. Sixty-seven isolates originated
from Europe (61 isolates from France and 6 from
Switzerland). The French CA-MRSA isolates originated
from 10 different hospitals located throughout France, and
the Swiss isolates were from the Geneva area. Seventeen
isolates were from Oceania and included two different
clones: 1) 13 isolates corresponded to the Western
Samoan phage pattern strains, also designated the
Southwest Pacific clone (9) and were isolated from
Australia (8 isolates), New Zealand (4 isolates), and
Western Samoa (1 isolate) (5); 2) 4 other isolates from
Australia belonged to a recently described clone designat-
ed as the Queensland clone (10). The Southwest Pacific
clone has two distinct phage-typing patterns known as
Western Samoan Phage Pattern (WSPP) 1 and 2 (5). The
Queensland clone, which cannot be phage typed, was first
detected in the southeast Queensland city of Ipswich in
2000 (10). Most isolates were from primary skin and soft
tissue infections, with some cases of bacteriemia and at
least five cases of necrotizing pneumonia (2,3,9,11,12).
A set of representative hospital-acquired (HA)MRSA
isolates was included in the study: 24 from France and 33
from the United States. French HA-MRSA isolates corre-
sponded to those of the major clones isolated throughout
France as described by Lelievre et al. (13). HA-MRSAiso-
lates were recovered from the same 12 different facilities
that CA-MRSA. HA-MRSA from the United States origi-
nated from the same geographic area as the CA-MRSA.
Antimicrobial Susceptibility Testing 
The MICs of benzyl-penicillin, oxacillin, gentamicin,
tobramycin, kanamycin, chloramphenicol, tetracycline,
minocycline, erythromycin, lincomycin, pristinamycin,
fusidic acid, rifampicin, ofloxacin, co-trimoxazole, line-
zolid, mupirocin, vancomycin, and teicoplanin were deter-
mined for selected isolates (46 European, 22 U.S., and 13
Oceanian isolates) by using the standardized agar dilution
technique as recommended by the French Society for
Microbiology (14).
Detection of Accessory Genes by PCR
Using polymerase chain reaction (PCR), we determined
the presence of accessory gene regulator (agr) allele group
(1–4), SCCmec element (I-IV, according to the designation
of Oliveira [15]), and 22 specific staphylococcal virulence
genes (including 16 super-antigenic toxins, 3 hemolysins,
and 3 leukocidins), as described previously (16). 
Amplification of gyrA was used as a quality control of
each DNA extract and the absence of PCR inhibitors. S.
aureus strains Fri 913 (sea, see, sec, tst, lukE lukD, sek, sel,
sep, and hlg), Fri 1151m (sed, sej, lukE lukD, hlgv, and
hlb), ATCC 14458 (CCM5757) (seb, lukE lukD, sek, and
hlgv), NCTC 7428 (sec, tst, lukM, seg, sei, sem, sen, seo,
lukE lukD, hlgv, and hlb), A92 0211 (seg, sei, sem, sen,
seo, eta, etb, lukE lukD, and hlgv), RN6390 (lukE lukD,
hlgv, hlb, and agr1), RN6607 (sed, seg, sei, sem, sen, seo,
lukE lukD, hlgv, and  agr2), RN8465 (seg, sei, sem, sen,
seo, tst, hlg, and  agr3), RN4850 (seg, sei, sem, sen, seo,
eta, etb, lukE lukD, hlgv, and agr4), RN 6911(lukE lukD,
hlgv, hlb, agr null), E-1 (seg, sei, sem, sen, seo, lukE lukD,
eta, hlgv, edinB and C), ATCC 49775 (seg, sei, sem, sen,
seo, lukS lukF, and hlg), and ATCC 51811 (FRI 569) (seh,
lukE lukD, hlb, and hlgv) were used as positive controls for
PCR (17,18). S. aureus COL (SCCmec  I), PER34
(SCCmec IA), BK2464 (SCCmec II), ANS46 (SCCmec
III), HU25 (SCCmec IIIA), and HDE288 (SCCmec IV)
were used as controls for characterization of the mec ele-
ment according to Oliveira and de Lencastre (15). 
The overall genetic background of the isolates was
evaluated: 1) by digesting whole cell DNA with SmaI
macrorestriction enzyme and determining the fragment-
size patterns obtained on pulsed-field gel electrophoresis
(PFGE) using a contour-clamped homogeneous electric
field system on a CHEF DR-II apparatus (Bio-Rad
Laboratories, Marnes-la-Coquette, France) as previously
described (19). Resolved macrorestriction patterns were
compared as recommended by Tenover et al. (20). Isolates
differing by up to three fragments were considered as sub-
types of a given clonal type. MLST was performed as
described by Enright et al. (21). Briefly, seven housekeep-
ing genes were used in the scheme; for each isolate, the
alleles at each of the seven loci defined the allelic profile,
which corresponded to a sequence type (ST). ST designa-
tions were those assigned by the MLSTdatabase (available
from: URL: http://www.mlst.net).
Results
Distribution of Accessory Genes from 
MRSA in Three Continents
Overall, we detected 12 different virulence genes or
gene clusters among the 117 isolates (Table 1). Two gene
loci were common to CA-MRSA isolates from all loca-
tions. Methicillin resistance was conferred in all 117 CA-
MRSAisolates by the truncated SCCmec type IV element,
and all the isolates contained the PVL locus. In addition,
112 isolates harbored the related lukE-lukD genes of
another leukocidin frequently recovered from patients with
all types of staphylococcal infections (3). Most (113 [97%]
of 117) isolates were of agr type 3. 
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origin. The European and Southwest Pacific isolates had
consistent, relatively simple, patterns of virulence-associat-
ed genes. In addition to the SCCmec type IV element, PVL
genes, and lukE-lukD, all the European isolates were posi-
tive for hlg-v (the  γ-hemolysin variant gene) and the
Southwest Pacific isolates were positive for hlg (the  γ-
hemolysin gene) and egc (the enterotoxin gene cluster cod-
ing for the enterotoxins seg, sei, sem, sen, and seo) (Table
1). The Queensland isolates had not been tested positive for
the toxin genes, except the PVLlocus. In contrast, consider-
able variability existed among the 33 U.S. isolates. As for
the European isolates, the U.S. isolates showed both the
presence of hlg-v and the absence of hlg. However, seven
other toxins (the enterotoxins sea–sed, sej, she, and sek),
which were absent in non–U.S. isolates, were variously
found in up to 29 (3% to 87%) of these 33 isolates (Table 1).
Analysis of Genetic Background of CA-MRSA by PFGE
The 117 CA-MRSA isolates clustered into six PFGE
clonal types (A to F, Figure). All 67 European isolates
grouped into seven related PFGE patterns (subtypes A1-7)
distinct from the other isolates. Most of the U.S. isolates
belonged to a closely related group of five patterns (sub-
types B1-5), although two well-differentiated outliers
existed, one (D1) containing three isolates and the other
(F1) containing only one isolate, both of which had an agr
type 1 genotype. The 13 isolates obtained from Australia,
New Zealand, and Western Samoa and belonging to the
Southwest Pacific clone showed three closely related
PFGE patterns (subtypes C1-3) with no geographic associ-
ation. The four isolates from Australia belonging to the
Queensland clone had the same E1 pattern. The phyloge-
netic tree shown on the left side of the figure confirms the
diversity in PFGE patterns between the CA-MRSA from
different continents. 
CA-MRSA Antibiotic Susceptibility Profiles
MICs were determined on a selected number of isolates
(81) that corresponded to the different PFGE patterns.
Overall, CA-MRSA isolates from all locations were sus-
ceptible to numerous antimicrobial drugs, including
tobramycin, gentamicin, lincomycin, pristinamycin,
minocycline, chloramphenicol, ofloxacin, vancomycin,
teicoplanin, fosfomycin, rifampin, co-trimoxazole, and
linezolid (Table 2). For the purposes of assessing differ-
ences between locations, isolates from the United States
and Oceania were combined since their susceptibility pro-
files were similar (Table 2). Minor heterogeneity in eryth-
romycin and mupirocin susceptibility was noted among
European isolates. In contrast, U.S. and Oceanian isolates
were uniformly susceptible to these antibiotics (Table 2).
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Table 1. Distribution of virulence and resistance determinants in 117 CA-MRSA isolates from three continents  



















Sequence type  80  1  59 or 8  30  93   
PFGE pattern  A1-7  B1-5  D1 & F1  C1-3  E1   
agr type  3  3  1  3  3   
SCC IV  67 (100)  29 (100)  4 (100)  13 (100)  4 (100)  117 (100) 
Leukocidins PVL genes  67 (100)  29 (100)  4 (100)  13 (100)  4 (100)  117 (100) 
lukE-lukD  67 (100)  29 (100)  3 (75)  13 (100)  0 (0)  116 (99) 
Hemolysins
e             
hlg  0 (0)  0 (0)  0 (0)  13 (100)  0 (0)  13 (11) 
hlg-v  67 (100)  29 (100)  4 (100)  0 (0)  0 (0)  100 (85) 
hlb  0 (0)  0 (0)  1 (25)  0 (0)  0 (0)  1 (1) 
Enterotoxins sea  0 (0)  23 (79)  0 (0)  0 (0)  0 (0)  23 (20) 
seb  0 (0)  8 (28)  1 (25)  0 (0)  0 (0)  9 (8) 
sec  0 (0)  20 (69)  0 (0)  0 (0)  0 (0)  20 (17) 
sed-sej  0 (0)  0 (0)  3 (75)  0 (0)  0 (0)  3 (3) 
seh  0 (0)  29 (100)  0 (0)  0 (0)  0 (0)  29 (25) 
sek  0 (0)  24 (83)  0 (0)  0 (0)  0 (0)  24 (21) 
egc
f  0 (0)  0 (0)  0 (0)  13 (100)  0 (0)  13 (11) 
aPFGE, pulsed-field gel electrophoresis; PVL, Panton-Valentine leukocidin.
 
bResults for toxin genes absent from all community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) isolates (see, tst, eta, etb, lukM, and edinA) are not 
presented. 
cIsolates from France (61) and Switzerland (6). 
dIsolates from Australia (8), New Zealand (4), and Western Samoa (1). 
ehlg, γ hemolysin gene; hlg-v, γ-hemolysin variant gene; hlb, β-hemolysin gene. 
fegc: enterotoxin gene cluster, which includes the seg, sei, sem, sen, and seo gene. The main difference between the two groups was their sus-
ceptibility to kanamycin, tetracycline, and fusidic acid,
with the European group of isolates being more resistant
than the U.S. and Oceanian group (Table 2).
Comparison of CA-MRSA with HA-MRSA
Using PFGE to compare CA-MRSA isolates with rep-
resentative HA-MRSA isolates from both France (24 iso-
lates) and the United States (33 isolates), we found that the
last isolates grouped into lineages that clearly differed
from any of the CA-MRSA isolates of the same continent
(not shown). None of the HA-MRSA harbored PVL genes
or the SCCmec IV element. Moreover, all U.S. HA-MRSA
had SCCmec type II element; most (31 of 33) of these iso-
lates were agr type 2, and the remaining 2 were type 1.
Conversely, all French HA-MRSA had an unknown
SCCmec element according to the method of Oliveira (15).
These strains were further designated as SCCmec IVc by
Hiramatsu (22). Twenty-three of the 24 French HA-MRSA
isolates were agr type 1, and only 1 was a type 2. None of
the HA-MRSA tested was agr type 3, the predominant
type for CA-MRSA. In addition, unlike the PVL genes,
lukE-lukD leukocidin genes were found in most HA-
MRSA (95%) as well as in CA-MRSA.
Analysis of Genetic Background by MLST
Twenty-one representative isolates of each PFGE pat-
tern of CA-MRSA were further characterized by MLST.
Overall, the results perfectly matched those of the PFGE
with a unique ST corresponding to each group of related
PFGE patterns (Table 1). The STs of CA-MRSA were
compared with those in the MLST database (Table 3).
Within each continent, the most frequent STs of CA-
MRSA (i.e., ST1 for the U.S. clone, ST30 for the
Southwest Pacific clone, and ST80 for the European clone)
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Figure. Pulsed-field gel electrophoresis (PFGE) pattern and phylo-
genetic tree of 117 community-acquired (CA)-methicillin resistant
Staphylococcus aureus isolates from three continents. SmaI
macrorestriction patterns were digitized and analyzed by using
Taxotron software (Institut Pasteur, Paris, France) to calculate
Dice coefficients of correlation and to generate a dendrogram by
the unweighted pair group method using arithmetic averages
(UPGMA) clustering. The scale indicates the level of pattern simi-
larity. Capital letters indicate macrorestriction types based on visu-
al interpretation of PFGE results. 
Table 2. MIC50 and MIC90 of staphylococcal antibiotics against community-acquired methicillin resistant Staphylococcus aureus (CA-
MRSA) from Europe (46 isolates), United States (22 isolates), and Oceania (13 isolates) 
Isolates from Europe  Isolates from United States and Oceania 
Antibiotics  MIC50 mg/L  MIC90 mg/L  Range mg/L  MIC50 mg/L  MIC90 mg/L  Range mg/L 
Benzyl-penicillin  8  8  0.25–8  16  16  4–32 
Oxacillin  16  32  4–64  64  64  16–64 
Kanamycin  128  128  128  2  2  2 
Tobramycin  0.25  0.25  0.25  0.25  0.25  0.25 
Gentamicin  1  1  0.5–1  1  1  0.5–2 
Erythromycin  0.5  128  0.25–128  0.25  0.5  0.25–128 
Lincomycin  0.5  0.5  0.5–32  0.5  0.5  0.25–32 
Pristinamycin  0.5  0.5  0.12–1  0.5  0.5  0.12–1 
Tetracycline  16  16  0.25–16  0.25  0.25  0.25–32 
Minocycline  0.25  0.25  0.25  0.25  0.25  0.25 
Chloramphenicol  4  4  4–8  4  8  4–8 
Ofloxacin  0.12  0.12  0.12–0.5  0.12  0.25  0.12–1 
Fusidic acid  4  4  0.12–64  0.12  0.12  0.12 
Vancomycin  0.5  0;5  0.5–1  0.5  0;5  0.5–1 
Teicoplanin  0.5  0.5  0.25–0.5  0.25  0.5  0.25–0.5 
Fosfomycin  2  2  0.25–2  1  2  0.25–2 
Rifampin  0.12  0.12  0.12  0.12  0.12  0.12 
Co-trimoxazole  0.5/9.5  0.5/9.5  0.5/9.5  0.5/9.5  0.5/9.5  0.5/9.5 
Linezolid  0.5  1  0.25–1  0.5  1  0.25–1 
Mupirocin  0.12  0.12  0.12–8  0.12  0.12  0.12 were different than the STs of HA-MRSA or methicillin-
susceptible S. aureus (MSSA) strains in the same conti-
nent. For instance, ST1 was detected in U.S. CA-MRSA
but only in European MSSA. The only correlation within a
continent between the ST of MSSA and CA-MRSA was
for the two rare agr1 CA-MRSA clones from the United
States (STs 8 and 59). Thus, these two infrequent STs of
CA-MRSA were also observed in MSSA (ST8) and HA-
MRSA (ST8 and 59) in the same country.
Discussion
The characterization of 117 CA-MRSA isolates from
three continents indicted four major findings. First, only
two genes were unique to CA-MRSA isolates and shared
by isolates from all three continents: a type IV SCCmec
cassette (further designated IVa by Okuma et al. [4]) and
the PVL locus. Otherwise, the distribution of the other
toxin genes was continent-specific. This finding suggests
that PVL and SCCmec  type IV may confer a selective
advantage for community-based MRSA pathogens.
Second, CA-MRSA isolates were generally susceptible to
most of antibiotics tested apart from β-lactams, although
European isolates appeared more resistant (i.e., to
kanamycin, tetracycline, and fusidic acid) than U.S. and
Oceanian isolates. Third, the genetic background of CA-
MRSA organisms was different in each of the three conti-
nents, although it was predominantly restricted to the agr3
background, which corresponds to one of the three major
phylogenetic lineages of pathogenic MSSA previously
described (16). This finding demonstrates that dissemina-
tion of a single CA-MRSA clone did not occur around the
world but rather suggests the possibility of simultaneous
co-evolution of CA-MRSA organisms in different loca-
tions. Fourth, MLST and PFGE analysis showed that with-
in a continent, the genetic background of CA-MRSA
strains did not correspond to that of the HA-MRSA in the
same continent, suggesting that CA-MRSAdid not emerge
from local HA-MRSA.
The STs of CA-MRSA clones were not related to the
STs of any described pandemic clones of MRSA, such as
the Archaic clone (ST250 with a SCCmec I element), the
Iberian clone (ST247 with a SCCmec IA element), the
New York/Japan clone (ST5 with a SCCmec II element),
the Hungarian clone (ST239 with a SCCmec III element),
the Brazilian clone (ST239 with a SCCmec IIIA element),
or the pediatric clone (ST5 with a SCCmec IV element)
(23). However, analysis of the MLST database indicated
that the CA-MRSA of each continent shared a common
genetic background with HA-MRSA or MSSA of other
continents (Table 3). This suggests that intercontinental
exchange of MRSA or MSSA had occurred, possibly fol-
lowed by the introduction of the SCCmec in MSSAand the
PVL locus in MSSA or MRSA. However, we cannot rule
out the converse hypothesis that, for instance, MRSA of
ST8 from France, which do not harbor the PVL locus and
are of agr1 allele, derive from an ancestor of agr1 allele
found in the United States, carrying the PVL locus (Table
3 and data not shown). In any case, the association of
SCCmec IV (SCCmecIVa according to Baba et al. denom-
ination [6]) with PVL in the CA-MRSA strains most like-
ly did not result from co-acquisition of the two determi-
nants on a single mobile genetic element because the two
loci are widely separated on the S. aureus chromosome (6). 
The CA-MRSAisolates contained the SCCmec type IV
element, according to the designation of Oliveira and de
Lencastre (15). If MRSA isolates with the SCCmec type
IV element contained an additional 381–base pair band
because of the integration of pUB110, the isolates are said
to be SCCmec IVA. However, other groups in Japan and
the United States have used region-specific primers to
define the L-C region of the SCCmec element (4). On the
basis of L-C polymorphism, researchers have identified
three types to date, designated IVa, IVb, and IVc. Thus, the
IVa of these latter groups (4) is not the same as the IVA of
Oliveira and de Lencastre (15).
The exact nature of the selective advantage conferred
by the observed combination of genetic traits remains to be
elucidated, but simple antibiotic selection seems unlikely
in a community context of widely different populations
with various degrees of methicillin exposure. Okuma et al.
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Table 3. Origin and frequency of Staphylococcus aureus isolates according to their sequence types  
  Present study  Data from the MLST Web site 
Sequence type  Country of origin of CA-MRSA  n  Country of origin of MSSA  n  Country of origin of MRSA  n 
1  USA  29  UK, Denmark, the Netherlands, 
Canada, 
20    0 
8  USA  3  UK, the Netherlands, Denmark, 
US, Canada 
46  Scotland, Ireland, Australia, 
U.S., UK, Germany, The 
Netherlands, France 
39 
30  Oceania (Southwest Pacific clone)  13  UK, Denmark, Germany  83  UK, Spain, Germany, 
Sweden 
8 
59  USA  1  UK  4  U.S.  1 
80  France, Switzerland  67    0  Greece  1 
93  Australia (Queensland clone)  4    0    0 
aMLST, multi-locus sequence typing ; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; CA, community acquired. (4) suggested that CA-MRSA should display enhanced
ecologic fitness, as they had a shorter doubling time than
HA-MRSA. The real impact of this in vitro observation
needs to be evaluated. Unlike other SCCmec elements,
SCCmec IV and SCCmec I do not code for additional
resistance determinants; however, SCCmec IV does code
for mecA, a peptidoglycan transpeptidase. This protein is
expressed at the external surface of the cytoplasmic mem-
brane, where it could interact with the extracellular protein
PVL. We are investigating the possibility of PVL activity
or of peptidoglycan formation as a result of such an asso-
ciation. 
CA-MRSA infections appear to be an emerging phe-
nomenon worldwide. The PVL locus represents a stable
genetic marker of these CA-MRSAstrains, which explains
the frequency of primary skin infections and occasionally
necrotizing pneumonia associated with these strains
(2,8,24,25). Although the selective advantage conferred by
the combination of genetic traits (i.e., PVL locus and
SSCmec IV in an agr3 background) is not clear, the spread
of a limited number of clones in each continent suggests
that these CA-MRSA strains are particularly suited to be
successful community-based pathogens. 
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